Earnings and Growth Analysis : Supernus Pharmaceuticals Stock Forecast, Price & News (NASDAQ:SUPN)

0
167

Earnings results for Supernus Pharmaceuticals Stock Forecast, Price & News (NASDAQ:SUPN)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at 0.35 and remained the same over the past month at 0.35. Of the 1 analysts making quarterly forecasts, 1raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has increased over the past week from 1.49 to 1.58(6.04%) and increased over the past month from 1.44 to 1.49(3.47%). Of the 2 analysts making yearly forecasts, 2raised and none lowered their forecast.

Analyst Opinion on Supernus Pharmaceuticals Stock Forecast, Price & News (NASDAQ:SUPN)

4 Wall Street analysts have issued ratings and price targets for Supernus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $26.33, predicting that the stock has a possible upside of 5.76%. The high price target for SUPN is $31.00 and the low price target for SUPN is $24.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of “Hold.”

Supernus Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings. According to analysts’ consensus price target of $26.33, Supernus Pharmaceuticals has a forecasted upside of 5.8% from its current price of $24.90. Supernus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Supernus Pharmaceuticals Stock Forecast, Price & News (NASDAQ:SUPN)

Supernus Pharmaceuticals does not currently pay a dividend. Supernus Pharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: Supernus Pharmaceuticals Stock Forecast, Price & News (NASDAQ:SUPN)

In the past three months, Supernus Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $397,935.00 in company stock. Only 7.86% of the stock of Supernus Pharmaceuticals is held by insiders. 92.73% of the stock of Supernus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Supernus Pharmaceuticals Stock Forecast, Price & News (NASDAQ:SUPN

Earnings for Supernus Pharmaceuticals are expected to grow by 22.15% in the coming year, from $1.49 to $1.82 per share. The P/E ratio of Supernus Pharmaceuticals is 11.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 17.56. The P/E ratio of Supernus Pharmaceuticals is 11.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.54. Supernus Pharmaceuticals has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here